Jéssica Barreto Ribeiro Dos Santos (Jessica Barreto Ribeiro Dos Santos, Jessica Barreto Ribeiro Dos Santos, Jéssica B Dos Santos)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 10

Top Topics

Metastatic Colorectal Cancer

Ejection Fraction

Rheumatoid Arthritis Patients

Disease Activity

Top Venues

Expert review of clinical immunology

Sao Paulo medical journal = Revista paulista de medicina

Einstein (Sao Paulo, Brazil)

Expert review of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Adriana Maria Kakehasi, Alessandra Maciel Almeida, Pedro Ricardo Kömel Pimenta, Juliana Álvares Teodoro, Francisco de Assis Acurcio
First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study. Sao Paulo medical journal = Revista paulista de medicina 140 (6) (2022)
Jéssica Barreto Ribeiro Dos Santos, Rosângela Maria Gomes, Michael Ruberson Ribeiro da Silva
Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience. Expert review of clinical immunology 18 (9) (2022)
Elisa Neide Barbosa de Souza, Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Edna Afonso Reis, Juliana Álvares Teodoro, Francisco de Assis Acurcio, Alessandra Maciel Almeida
Functionality assessment in patients with rheumatic diseases undergoing treatment in the Public Health System. Einstein (Sao Paulo, Brazil) 20 (2022)
Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva
Daridorexant for the treatment of insomnia disorder: findings and implications. European journal of clinical pharmacology 78 (11) (2022)
Pedro Ricardo Kömel Pimenta, Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Adriana Maria Kakehasi, Francisco de Assis Acurcio, Juliana Álvares Teodoro
Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study. Journal of comparative effectiveness research 10 (6) (2021)
Ana F Souza, Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Alessandra Maciel Almeida, Francisco de Assis Acurcio, Juliana Álvares Teodoro
Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study. Pharmacy practice 19 (2) (2021)
Haliton Alves de Oliveira Júnior, Tiago Pereira da Veiga, Francisco de Assis Acurcio, Alessandra Maciel Almeida, Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva, Adriana Maria Kakehasi, Mariângela Leal Cherchiglia
Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff. Hospital practice (1995) 48 (4) (2020)
Jéssica Barreto Ribeiro Dos Santos, Augusto Afonso Guerra Junior, Michael Ruberson Ribeiro da Silva, Alessandra Maciel Almeida, Francisco de Assis Acurcio, Juliana Álvares Teodoro
First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. Expert review of clinical pharmacology 12 (4) (2019)
Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Alessandra Maciel Almeida, Augusto Afonso Guerra Junior, Juliana Álvares Teodoro, Francisco de Assis Acurcio
Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations. Expert review of clinical immunology 15 (8) (2019)
Wânia Cristina da Silva, Vânia Eloisa de Araújo, Ellias Magalhães E Abreu Lima, Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva, Paulo Henrique Ribeiro Fernandes Almeida, Francisco de Assis Acurcio, Brian B Godman, Amanj Baker Kurdi, Mariângela Leal Cherchiglia, Eli Iola Gurgel Andrade
Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 32 (6) (2019)